Breaking News

BioDuro Expands Spray Drying Mfg. Capacity

November 8, 2016

Adds SPX Anhydro MicraSpray 150 at San Diego facility

BioDuro, LLC has expanded its manufacturing capacity with the addition of an SPX Anhydro MicraSpray 150 to its suite of GMP spray drying capabilities at its San Diego facility. This expanded capacity will support larger scale spray drying programs to 100 kg scale.

BioDuro currently performs clinical manufacture using its MicraSpray 35, and this new addition is directly scalable and will boost capacity to 15 kg/hr solvent evaporation with industry benchmark control and reproducibility. This processing capability is supported by downstream technologies including roller compaction by Gerteis MiniPactor, blending, and tablet compression that can support batch sizes at the 1-100 kg scale.

"With the continued rise in poorly soluble drug candidates coming out of discovery, the need to provide our clients with technologies that can overcome formulation challenges is a necessity. BioDuro has historically offered spray drying capabilities that enhance solubility of poorly soluble clinical candidates with proven 10-100 fold increases," said Cyrus K. Mirsaidi, president and chief executive officer at BioDuro. "The addition of the SPX Anhydro MicraSpray 150 will allow BioDuro to manufacture cGMP-compliant, pilot scale spray dried material with greater efficiency and reduced cycle times. We are excited to provide a more streamlined, cost-effective solution for our clients' drug development needs."

The MicraSpray 150 will be operationalat the San Diego site in 1Q17, where the company houses its formulation development and clinical manufacturing operations. 

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks